High Dose Bolus (HDB) Interleukin-2 (IL2) and Concurrent Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Advanced Melanoma after Failure of Anti-Pd1-based Immunotherapy and BRAF-MEK Inhibition.
Journal of Clinical Oncology（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要